---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-017211"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:36:31.881996+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Omeros Q1 net loss $0.58/sh; swaps $70.8M of 2026 notes for 2029 notes at 9.5%

## Summary
- Net loss $33.5M ($0.58/diluted) vs $37.2M ($0.63) a year ago; OMIDRIA royalties $6.7M on sales of $22.3M.
- Cash and short-term investments $52.4M at Mar 31, 2025, down $37.7M from Dec 31, 2024.
- Exchanged $70.8M of 5.25% 2026 notes for new 9.50% 2029 notes; additionally $10M notes converting to equity.
- Outstanding 2026 notes reduced to ~$17.1M; avoids $20M term loan prepayment plus $1M premium due Nov 2025.
- FDA accepted BLA for narsoplimab in TA-TMA; PDUFA date Sep 25, 2025. Phase 3 PNH program paused to conserve cash.

## SEC filing metadata
- accession: 0001437749-25-017211
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774925017211/0001437749-25-017211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774925017211/omer20250407_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-017211
- JSON: https://secwatch.observer/filing/0001437749-25-017211.json
- Plain text: https://secwatch.observer/filing/0001437749-25-017211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.